Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) – Pipeline Review, H1 2017’, provides in depth analysis on Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)Additionally, the report provides an overview of key players involved in Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Cardiovascular and Ophthalmology under development targeting Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)

The report reviews Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects

The report assesses Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

4SC AG

HitGen LTD

MEI Pharma Inc

Mirati Therapeutics Inc

Sigma-Tau SpA

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC

3.5.1.98) - Overview

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC

3.5.1.98) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC

3.5.1.98) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC

3.5.1.98) - Companies Involved in Therapeutics Development

4SC AG

HitGen LTD

MEI Pharma Inc

Mirati Therapeutics Inc

Sigma-Tau SpA

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC

3.5.1.98) - Drug Profiles

Gene Therapy to Activate HDAC4 for Heart Failure - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate HDAC4 for Retinitis Pigmentosa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HG-3001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mocetinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pracinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

resminostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-3595 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC

3.5.1.98) - Dormant Products

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC

3.5.1.98) - Discontinued Products

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC

3.5.1.98) - Product Development Milestones

Featured News & Press Releases

May 18, 2017: Helsinn Group and MEI Pharma Announce Upcoming Presentations of Gene Mutation and Clinical Response Data from Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

Jan 24, 2017: Overall survival benefit for resminostat in first-line liver cancer study subgroup

Jan 05, 2017: Mirati Therapeutics Provides Update On Mocetinostat Program

Dec 16, 2016: First patient enrolled in pivotal RESMAIN study of resminostat in CTCL

Dec 05, 2016: Helsinn Group and MEI Pharma Report Prolongation of Survival Results from Phase 2 Clinical Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

Nov 03, 2016: Helsinn Group and MEI Pharma Announce Long-Term Survival and Response Data from Phase II Clinical Study of Pracinostat in Acute Myeloid Leukemia Accepted for Oral Presentation at Upcoming American Society of Hematology Annual Meeting

Aug 01, 2016: MEI Pharmas Pracinostat Receives Breakthrough Therapy Designation from FDA for Treatment in Combination with Azacitidine of Patients with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Chemotherapy

Jun 05, 2016: Mirati Therapeutics Provides Update On Mocetinostat Program

May 27, 2016: 4SC provides headline results from Yakult Honsha’s Phase II trial of resminostat in combination with sorafenib as first line therapy in liver cancer

May 10, 2016: Subgroup analysis suggests survival benefit in patients with advanced liver cancer treated with resminostat

Mar 24, 2016: Mirati Therapeutics To Present Mocetinostat Preclinical Data At 2016 American Association For Cancer Research Annual Meeting

Feb 24, 2016: FDA approves IND application for resminostat in liver cancer

Dec 07, 2015: MEI Pharma Announces Positive Results from Phase II Study of Pracinostat in Acute Myeloid Leukemia, Plans to Initiate Phase III Registration Study

Oct 06, 2015: MEI Pharma Announces Data from Phase II Clinical Studies of Pracinostat Accepted for Oral Presentation at American Society of Hematology Annual Meeting

Sep 30, 2015: 4SC Receives Funding From The Eurostars Programme For Further Research Of Its Anti-Cancer Agent Resminostat With An Epigenetic Mode Of Action

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indication, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products under Investigation by Universities/Institutes, H1 2017

Products under Investigation by Universities/Institutes, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by 4SC AG, H1 2017

Pipeline by HitGen LTD, H1 2017

Pipeline by MEI Pharma Inc, H1 2017

Pipeline by Mirati Therapeutics Inc, H1 2017

Pipeline by Sigma-Tau SpA, H1 2017

Dormant Products, H1 2017

Dormant Products, H1 2017 (Contd..1), H1 2017

Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Top 10 Indications, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports